FDA timelines dictate your launch window, clinical evidence requirements shape your sales cycle, and reimbursement complexity determines your business model. You need a growth strategy built around these realities, not in spite of them.

The Problem

FDA timelines create unpredictable growth windows

Your commercial team can't plan hiring, channel investment, or territory expansion when 510(k) or PMA timelines shift by quarters. Every delay cascades into missed revenue targets and wasted marketing spend on pre-launch awareness that expires. Most medtech companies either start too late and scramble post-clearance, or spend too early and burn cash waiting for an approval date nobody can guarantee.

Clinical evidence requirements slow market adoption

Hospital procurement committees and physician champions need clinical outcomes data before they will consider your device. Building that evidence takes time, money, and relationships with KOLs who are already overcommitted. Most medtech startups treat clinical evidence as a regulatory checkbox rather than a commercial asset. The companies that grow fastest build clinical and commercial strategy at the same time.

Reimbursement complexity affects business model viability

Your device might work, but if payers won't cover it, hospitals won't buy it. CPT code coverage, prior authorization requirements, and payer mix variability across geographies make pricing and market entry decisions genuinely hard. Getting reimbursement wrong doesn't just slow growth. It kills unit economics and makes every customer acquisition more expensive than the last.

Hospital procurement cycles outlast your cash runway

Selling into health systems means navigating value analysis committees, group purchasing organizations, and IT integration requirements that stretch sales cycles to 12-18 months. Most medtech growth models underestimate the time and resources required to move from first meeting to signed contract. Add physician champion turnover and budget cycle timing, and you have a sales process that punishes companies without a disciplined approach.

How We Help

We build growth strategies for medtech companies that account for the regulatory, clinical, and reimbursement realities that make this industry different from every other vertical. No generic playbooks. No borrowed SaaS frameworks applied to a 510(k) product.

Our engagement starts with a growth infrastructure assessment. We map your regulatory timeline, clinical evidence portfolio, reimbursement landscape, and commercial capabilities against your revenue targets. This tells us where the gaps are and which ones matter most given your stage and runway.

From there, we build a regulatory-aligned growth roadmap — commercial activities that create value before FDA clearance. KOL relationship development, health economics positioning, early payer engagement, and market shaping with target hospital systems. The goal is to compress time-to-revenue after clearance by doing everything possible before it.

We treat clinical evidence as a commercial strategy, not just a regulatory requirement. We work with your clinical team to identify which data points matter most to procurement committees and how to package outcomes data into materials that accelerate the sales cycle.

For reimbursement, we build market entry models that account for payer coverage variability — CPT code strategy, health economics value propositions, and geographic prioritization based on reimbursement favorability.

What makes our approach different: we operate as embedded growth operators, not consultants. We own growth targets alongside your team and make resource allocation decisions with you. The fractional model gives you senior medtech growth expertise without the overhead of a full-time VP of Commercial, and the 90-day sprint structure means you see measurable progress at every phase.

We build measurement into every engagement from day one. Baseline metrics before we change anything. Monthly reporting on what is working and what needs adjustment. No vanity metrics — only indicators that connect to pipeline and revenue.

What we deliver

Regulatory-aligned growth roadmap that sequences commercial activities around FDA milestones
Clinical evidence commercialization framework that translates outcomes data into sales acceleration
Reimbursement-optimized market entry strategy with geographic and payer prioritization
Hospital procurement playbook covering value analysis committees, GPO strategy, and physician champion development

The medtech companies that grow fastest treat clinical evidence as a commercial strategy, not a regulatory checkbox.

Our Methodology

Our methodology follows a 90-day sprint adapted to regulated markets. In the first 30 days, we embed with your team to audit commercial infrastructure, map your regulatory timeline, evaluate your clinical evidence portfolio, and assess reimbursement readiness. We review KOL relationships, pipeline data, and health economics materials.

Days 30-60 focus on strategy development and early execution. We build a growth roadmap aligned to your FDA timeline and begin implementing the highest-impact changes, including measurement frameworks tied to real commercial metrics — pipeline velocity, KOL engagement quality, and payer coverage progress.

Days 60-90 shift to full execution. Growth systems are running, the team is aligned, and we are optimizing based on real data. By the end of the sprint, you have a commercial growth engine with clear ownership and a roadmap that works whether we stay on or not.

How We Work

Growth strategy engagements begin with a 2-3 week diagnostic. We audit your commercial infrastructure, map the competitive landscape, review your clinical evidence portfolio, and benchmark go-to-market capabilities against companies at similar regulatory stages.

Weeks 3-8 focus on strategy development and initial execution. We build a regulatory-aligned growth roadmap with clear milestones and launch early initiatives around KOL development, payer engagement, or hospital system targeting. Weekly syncs and bi-weekly reports keep the team aligned.

From month 3 onward, we are in optimization mode — scaling what works, adjusting what does not, and pressure-testing assumptions against real market feedback. Monthly strategy reviews with leadership ensure growth targets stay aligned with regulatory progress.

Typical engagements run 4-6 months with a dedicated growth lead embedded in your operating rhythm, attending leadership meetings, coordinating with clinical and regulatory teams, and making resource allocation decisions alongside your executives.

Regulatory-aligned growth strategy
Clinical evidence commercialization framework
Reimbursement-optimized market entry

If your healthcare & medtech company needs growth strategy leadership, we should talk.

Expand your marketing team output with our experts

Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.

Frequently asked questions

How do you build a growth strategy around unpredictable FDA timelines?

We sequence commercial activities into pre-clearance and post-clearance phases. Before clearance, we focus on KOL development, health economics positioning, early payer engagement, and market shaping with target hospital systems. When clearance arrives, you are not starting from zero. The commercial engine is already warm and time-to-revenue compresses significantly.

What role does clinical evidence play in your growth strategy?

Clinical evidence is the single most important commercial asset in medtech. We work with your clinical team to identify which outcomes data matters most to hospital procurement committees and physician decision-makers. Then we build that evidence into sales materials, KOL talking points, and payer value propositions. Companies that treat evidence as only a regulatory requirement leave their best sales tool on the shelf.

How do you approach reimbursement as part of market entry?

Reimbursement determines whether your growth model works or breaks. We map CPT code coverage across target payers and geographies, build health economics value propositions for payer audiences, and prioritize market entry in regions with favorable reimbursement dynamics. We also help structure pilot programs with hospital systems that generate the utilization data payers need to expand coverage.

How long does a medtech growth strategy engagement take?

Diagnostic and strategy development take 6-8 weeks. Implementation and optimization run 3-6 months depending on your regulatory stage and commercial complexity. The 90-day sprint gives you a functioning growth system with clear ownership and metrics. Most clients extend to a second sprint as they approach or pass regulatory milestones.

How is this different from hiring a healthcare marketing agency?

Agencies execute campaigns within defined channels. Growth strategy determines which markets to enter, how to structure your commercial model around reimbursement constraints, and how to turn clinical evidence into pipeline acceleration. We work at the strategic layer and make resource allocation decisions alongside your leadership team. Agencies are often part of the execution plan we build, but not a substitute for the strategy itself.

What does this cost compared to hiring a full-time VP of Commercial?

Growth strategy engagements typically run $15K-$30K per month depending on scope. A full-time VP of Commercial in medtech costs $250K-$400K fully loaded, takes 4-6 months to recruit, and carries real hiring risk in a specialized talent market. The fractional model gives you experienced medtech growth leadership immediately, with flexibility to scale as milestones evolve.